Miacalcic (calcitonin) Important Safety Information from Novartis as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 20/08/2012

 

Problem Or Issue:
Important Safety Information communication from Novartis on calcitonin associated with malignancy – withdrawal of Miacalcic 200IU nasal spray, solution from the market.

Important Safety Information - Miacalcic


« Back